🔗 Share this article

While the United States proceeds with unprecedented changes to its immunization recommendations, an unexpected name has emerged somewhat surprisingly: Høeg, a US-based physician and public health researcher who first made her name by expressing skepticism about COVID-19 vaccinations in the pandemic and has zeroed in on potential deaths after COVID-19 immunization in her recent tenure at the FDA.

Proposed Overhauls to Childhood Vaccine Program

Public health authorities planned to reveal radical changes to the childhood immunization program earlier this month, synchronizing the US with Denmark’s immunization schedule, sources say – a substantial departure that would put the US out of step with many the global community with little proof for benefit. The announcement has been pushed back until the coming year.

In place of the top vaccines chief, Tracy Beth Høeg is scheduled to speak at the meeting. She was recently named temporary leader of the FDA’s CDER, the fifth appointee to head the division this calendar year.

Consolidating Power at the Agency

The acting appointment may indicate a closer partnership between the drug and vaccine centers as Høeg and Prasad strengthen their influence at the FDA – and it signals a increased emphasis upon reevaluating already-approved immunizations at the FDA.

Høeg has repeatedly called for discontinuing certain childhood shot schedules in the US so as to align more like the Danish model, a country with universal health coverage and a citizenry roughly the size of Wisconsin’s.

In her initial public appearances, she has persisted in emphasizing on immunizations – usually the domain of Prasad, head of the FDA’s CBER – rather than drug regulation.

Doubts Over Qualifications

The appointee has little discernible experience in drug development, approval processes or leadership, which has been typical for past heads of the biologics center. She has served at the FDA as a key advisor to the commissioner and CBER since March.

“It seems she lacks to have the necessary background” for overseeing the CDER, stated Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in running a major agency. She is not an expert in pharmaceutical oversight.”

Past heads of CBER would “grasp laws and regulations and the research of pharmaceutical innovation”, noted a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that prior appointees who ran CBER have had.”

The drug center has an immense workload at the agency, she stated.

“Many people just focuses on the innovative therapies, but the generic drug division authorizes thousands of off-brand pharmaceuticals. There’s a biosimilars program, over-the-counter program and other areas, and every single one must be looked after,” Dr. Woodcock noted. “The responsibility you neglect, that is the part that I always told people is going to come back to haunt you.”

Additionally, a substantial leadership component to the role, which oversees over 5,000 staff members. “It is a massive leadership role, if you execute it properly,” the former official said.

Official Statement and Disputed Initiatives

Regarding inquiries about Høeg’s credentials and whether this appointment indicates more teamwork among regulatory chiefs on immunizations, a press secretary said that the “concerns stem from inaccurate presumptions”.

“Her resume matches the duties of her position,” the representative stated, citing the months Dr. Høeg spent guiding the FDA commissioner on “medication safety and regulatory science, including computerized risk analysis and shot safety tracking”.

In her interim role, Høeg inherits the agency head's controversial expedited review system, a disputed rapid therapy clearance system that reportedly troubled her former heads. “By what process are these drugs being picked for this fast-track system? Who makes the calls?” Howard asked. “There is a lot of secrecy happening at the regulatory body right now.”

Broadly speaking, he remarked, “the agency seems to be moving towards laxer regulations of pharmaceuticals, with the exception of vaccines.”

Documented Past Work on Immunizations

With vaccines, Dr. Høeg has a more established, if concerning, history, critics have noted. She published a analysis using unconfirmed public submissions to assess the rate of heart inflammation following COVID-19 vaccination. She counseled the Florida top health official Joseph Ladapo, who reportedly have changed statistics to indicate Covid vaccines are riskier than they are.

Among her “desired changes” for the incoming government encompassed changing regulations for new vaccines and halting “optional” immunizations, she remarked after the election on a audio program. At the agency, Dr. Høeg has allegedly suggested barring teenage boys from obtaining COVID-19 vaccines.

“She’s an all-around dogmatist who begins with her preconceived notions and reverse-engineers to fit the evidence in a very deceptive, dishonest fashion,” Dr. Howard said.

Gaining Influence and a “Push for Payback”

Dr. Høeg joined fellow contrarians, {like|